Niravath, Polly http://orcid.org/0000-0003-0530-8883
Hilsenbeck, Susan G.
Wang, Tao
Jiralerspong, Sao
Nangia, Julie
Pavlick, Anne
Ademuyiwa, Foluso
Frith, Ashley
Ma, Cynthia
Park, Haeseong
Rigden, Caron
Suresh, Rama
Ellis, Matthew
Kent Osborne, C.
Rimawi, Mothaffar F.
Article History
Received: 30 May 2019
Accepted: 8 June 2019
First Online: 19 June 2019
Compliance with ethical standards
:
: Dr. Nangia has had a consultant/advisory role with Puma, and she has received funding from Paxman Coolers. Dr. Ademuyiwa has had a consultant/advisory role with Immunomedics, AstraZeneca, Jounce, Eisai, and Best Doctors; she has received funding from Pfizer, Abbvie, Seattle Genetics, Immunomedics, and Polyphor. Dr. Ellis has had a consultant/advisory role with NanoString, Novartis, AstraZeneca, Pfizer, Abbvie, Sermonix, and Puma; he has stock ownership in Bioclassifier with Royalty income from Prosigna/NanoString. Dr. Osborne has had a consultant/advisory role with Puma, AstraZeneca, and Genentech; stock ownership in GENETEX; and funding from Puma. Dr. Rimawi has had a consultant/advisory role in MacroGenics, Daiichi, and Novartis; he has received funding from Novartis and Pfizer. Dr. Ma has had a consultant/advisory role with Pfizer, Novaris, and Lilly; she has received funding from Eisai, Puma, and Pfizer.
: All procedures and processes in this clinical trial comply with all regulatory laws in the United States, where the study was conducted. All procedures performed in studies involving human participants were in accordance with the ethical standards of the Baylor College of Medicine Institutional Review Board and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.